retatrutide for obesity Weight loss with as compared to currently licenced Retatrutide Phase 3: 60% Achieved

doi: 10.3389/fphys.2022.983961 Received 01 July 2022 Accepted 07 September 2022 Published 20 September 2022 Volume 13 - 2022 Edited by Claudio de Lucia, Scientific Clinical Institute Maugeri (ICS Maugeri), Italy Reviewed by Oscar Lorenzo, Health Research Institute Foundacion Jimenez Diaz (IIS-FJD), Spain Raffaele Carraro, La Princesa University Hospital, Spain Updates Copyright 2022 Kreiner, Hovingh and von Scholten

Serious adverse events are rare

Always involve your prescriber

In the SURMOUNT-1 trial, tirzepatide produced dose-dependent weight reductions, with average losses approaching or exceeding ~20% at higher doses in adults with obesity who did not have diabetes, numbers that markedly exceed historical pharmacotherapy benchmarks

Cozy Holiday Chicken & White Bean Soup (Heartwarming soup) Comforting, filling, and gentle for GLP-1, which slows digestion

How Much Weight Could You Lose